The Open Mycology Journal

2010, 4 : 22-32
Published online 2010 June 24. DOI: 10.2174/1874437001004010022
Publisher ID: TOMYCJ-4-22

A General Overview on Past, Present and Future Antimycotics

G. Van Minnebruggen , I.E. J.A. Francois , B. P.A. Cammue , K. Thevissen , V. Vroome , M. Borgers and B. Shroot
Barrier Therapeutics n.v., a wholly owned subsidiary of Stiefel Laboratories, cipalstraat 3, B-2440, Belgium.

ABSTRACT

Since the discovery of amphotericin B in 1955 the armamentarium of antimycotic drugs now embraces many new chemical classes: azoles, allylamines and candins. However, despite the wide variety in chemical structure, there is a lack of diversity in terms of mechanism of action. The mechanism of action of the main classes of antimycotics as well as the therapeutic value of some representatives is discussed. Some challenges to innovation will be highlighted that when overcome will herald more effective therapeutic interventions. Finally, we will list antimycotics that are at a late stage of development.